expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
Published 2 years ago • 3.1K plays • Length 1:02:48Download video MP4
Download video MP3
Similar videos
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
1:16:18
serds at the inflection point in pretreated er /her2- breast cancer: novel er-targeting therapies
-
1:40:47
clarifyingcomplexities of expandingtreatmentoptionsfor advancedandearly-stage hr /her2- breastcancer
-
1:16:56
navigating the integration of trop2-targeted therapy in tnbc and hr , her2- breast cancer
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
1:20:02
her2-low expression in breast cancer: opportunities for expanding treatment benefit to more patients
-
25:28
episode 2: oral serds in er breast cancer: treatment selection and beyond
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
5:54
oral serds: new endocrine therapy options in er metastatic breast cancer - a patient case video
-
6:46
treatment options in her2 metastatic breast cancer
-
29:21
new advances and opportunities for improvement in hr /her2- early breast cancer
-
51:24
her2 and her3 alterations as therapeutic targets of increasing significance in solid tumors
-
4:07
new advances in hormonal therapies for er-positive breast cancer
-
1:33:57
evaluating the evidence and parsing the practicalities of therapeutic choices in hr breast cancer
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
1:30:06
moving toward expanded precision treatment of her2- or her3-driven breast, gi, lung & other cancers